Published on

Medicine – Disseminated Intravascular Coagulation (DIC)

Disseminated intravascular coagulation (DIC) is a life-threatening, acquired syndrome characterised by widespread activation of coagulation, formation of microvascular thrombi, consumption of platelets and coagulation factors, and potentially severe bleeding and organ dysfunction.

DIC is also known as consumption coagulopathy.

Important Clinical Principle

The characteristic feature of DIC is the simultaneous occurrence of thrombosis and bleeding. Microvascular fibrin deposition contributes to organ dysfunction, while consumption of platelets and coagulation factors contributes to haemorrhage.

1. Pathophysiology of DIC

DIC is triggered by excessive activation of the coagulation system, commonly through tissue factor exposure and inflammatory pathways.

  1. Procoagulant activation: Tissue factor and other procoagulant pathways activate coagulation.
  2. Excessive thrombin generation: Widespread coagulation activation occurs.
  3. Fibrin deposition: Fibrin-rich microthrombi form within small blood vessels.
  4. Consumption: Platelets and coagulation factors are consumed.
  5. Fibrin turnover: Fibrinolysis produces fibrin degradation products and D-dimer.
  6. Clinical consequences: Bleeding, microvascular thrombosis and organ dysfunction develop.
Important Clarification: DIC involves excessive activation and consumption of coagulation factors and platelets, rather than simply their massive release. Fibrinolysis varies according to the cause: it may be suppressed in sepsis-associated DIC or particularly prominent in some obstetric and malignancy-associated forms.

Illustration: Pathophysiology Flowchart

Underlying Trigger Sepsis, trauma, malignancy, obstetric event Coagulation Activation Tissue factor and thrombin generation Widespread Fibrin Formation Microvascular thrombi Consumption Platelets and factors become depleted Bleeding Microvascular Occlusion Impaired tissue perfusion and ischaemia Organ Dysfunction Fibrin Turnover / Fibrinolysis Increased D-dimer and FDP Degree of fibrinolysis varies by cause DIC = Thrombosis + Bleeding

2. Laboratory Findings in DIC

Investigation Typical Finding
Prothrombin time (PT)Prolonged
Activated partial thromboplastin time (aPTT)Prolonged; may be normal early
Thrombin time (TT)Normal or prolonged
Bleeding time (BT)May be prolonged; rarely used clinically
Platelet countDecreased (thrombocytopenia)
FibrinogenReduced or falling; may initially be normal or increased
Fibrin degradation products (FDP)Increased
D-dimerIncreased, often markedly
Peripheral blood filmMay show schistocytes (fragmented erythrocytes)

Explanation of Laboratory Abnormalities

  • Prolonged PT and aPTT: Consumption of coagulation factors.
  • Thrombocytopenia: Platelet activation and consumption within microthrombi.
  • Elevated D-dimer: Breakdown of cross-linked fibrin.
  • Reduced fibrinogen: Consumption during widespread fibrin formation.
  • Schistocytes: Mechanical fragmentation of erythrocytes within the microcirculation.
Examination Point: A normal fibrinogen concentration does not exclude DIC, especially in early or sepsis-associated disease. Serial laboratory measurements are often more informative than a single result.

3. Causes of DIC

A. Obstetric Causes

Cause Mechanism
Placental abruption (retroplacental haemorrhage)Release of tissue factor from damaged placental tissue
Retained dead fetusMay trigger coagulation activation, particularly with prolonged retention
Amniotic fluid embolismSudden inflammatory and coagulation activation
Severe pre-eclampsia / HELLP syndromeEndothelial injury and coagulation activation
Septic abortionSepsis-associated coagulation activation
Severe postpartum haemorrhageMay be associated with DIC in severe obstetric complications

B. Non-Obstetric Causes

Cause Clinical Significance
Sepsis / septicaemiaMajor cause, particularly severe bacterial sepsis
Major trauma / crush injuryTissue injury and systemic inflammatory activation
MalignancyParticularly acute promyelocytic leukaemia and certain adenocarcinomas
Severe liver diseaseMay coexist with DIC or produce similar laboratory abnormalities
Acute haemolytic transfusion reactionSystemic coagulation activation
Fat embolism syndromeMay be associated with coagulation activation and DIC
Severe pancreatitisInflammation and tissue injury
Major burnsTissue damage and systemic inflammation
Examination Point: Sepsis, major trauma, obstetric complications and malignancy are particularly important triggers of DIC.

4. Clinical Features of DIC

DIC may present predominantly with bleeding, thrombosis or organ dysfunction.

A. Bleeding Manifestations

  • Oozing from venepuncture sites or surgical wounds.
  • Petechiae, purpura and ecchymoses.
  • Epistaxis and gingival bleeding.
  • Gastrointestinal bleeding.
  • Haematuria.
  • Severe postpartum haemorrhage.

B. Thrombotic and Organ Manifestations

  • Acute kidney injury.
  • Respiratory failure.
  • Altered mental status.
  • Digital ischaemia.
  • Skin necrosis or purpura fulminans.
  • Multiorgan dysfunction.

5. Diagnosis of DIC

DIC is diagnosed using the clinical context together with laboratory abnormalities. No single investigation confirms or excludes DIC.

The International Society on Thrombosis and Haemostasis (ISTH) overt DIC score is commonly used in patients with an underlying condition associated with DIC.

ISTH Overt DIC Scoring System

Parameter Score
Platelets ≥100 × 109/L0
Platelets 50–99 × 109/L1
Platelets <50 × 109/L2
No increase in fibrin-related markers0
Moderate increase in fibrin-related markers2
Strong increase in fibrin-related markers3
PT prolongation <3 seconds0
PT prolongation 3–6 seconds1
PT prolongation ≥6 seconds2
Fibrinogen ≥1 g/L0
Fibrinogen <1 g/L1
ISTH Interpretation

A total score of 5 or more is compatible with overt DIC in the appropriate clinical setting.

A score below 5 does not exclude evolving DIC; repeat assessment may be required. The scoring system should only be applied when an underlying disorder associated with DIC is present.

6. Treatment of DIC

The fundamental principle is to treat the underlying cause while providing appropriate supportive care.

A. Treat the Underlying Cause

  • Sepsis: Prompt antimicrobial therapy and source control.
  • Obstetric DIC: Urgent treatment of the obstetric emergency.
  • Trauma: Haemorrhage control and resuscitation.
  • Acute promyelocytic leukaemia: Urgent specialist-directed treatment, including all-trans retinoic acid (ATRA) when suspected.

B. Blood Component Replacement

Blood Component Indication
Packed red blood cellsSignificant bleeding or anaemia requiring transfusion
PlateletsActive bleeding with thrombocytopenia, or preparation for high-risk procedures
Fresh-frozen plasma (FFP)Active bleeding or invasive procedures with significant coagulation factor deficiency
Cryoprecipitate / fibrinogen concentrateBleeding with low fibrinogen

In actively bleeding patients, clinicians commonly aim for a platelet count of at least 50 × 109/L and adequate fibrinogen replacement, often targeting at least 1.5 g/L in major haemorrhage, according to the clinical situation and local protocols.

C. Anticoagulation

Heparin is not routinely administered to every patient with DIC.

Therapeutic anticoagulation may be considered when thrombosis predominates, such as documented venous thromboembolism or selected cases of digital ischaemia, after specialist assessment of bleeding risk.

Patients with DIC who are not actively bleeding may also require standard VTE prophylaxis when appropriate.

D. Supportive Management

  • Haemodynamic resuscitation.
  • Oxygenation and organ support.
  • Serial monitoring of platelet count, PT, aPTT, fibrinogen and D-dimer.
  • Management of shock, renal failure and other complications.

7. Treatment Flowchart

DIC Diagnosed Urgent clinical assessment Treat Underlying Cause Sepsis, trauma, obstetric cause, cancer Assess Bleeding / Thrombosis Review haemostasis and organ function Bleeding Predominant Red cells if indicated Platelets / FFP Cryoprecipitate Thrombosis Predominant Consider anticoagulation Assess bleeding risk Specialist guidance Supportive Care + Serial Monitoring

8. DIC Versus Thrombotic Thrombocytopenic Purpura (TTP)

Feature DIC TTP
Primary mechanismSystemic coagulation activationSevere ADAMTS13 deficiency with platelet-rich microthrombi
Platelet countDecreasedDecreased
SchistocytesMay be presentCommon
PT / aPTTOften prolongedUsually normal
D-dimerOften markedly increasedVariable
FibrinogenMay be decreasedUsually normal
Main treatmentTreat cause and support coagulationUrgent plasma exchange and specialist therapy

9. High-Yield Examination Summary

Aspect Important Point
DefinitionSystemic coagulation activation with consumption of platelets and factors
PathophysiologyThrombin generation, fibrin deposition, consumption and variable fibrinolysis
Laboratory findingsProlonged PT/aPTT, thrombocytopenia, elevated D-dimer, falling fibrinogen
Blood filmMay show schistocytes
Major causesSepsis, trauma, malignancy, obstetric emergencies
DiagnosisClinical context, serial laboratory tests and ISTH score
TreatmentTreat underlying cause, blood components when indicated, supportive care
HeparinReserved for selected thrombotic presentations

10. Key Examination Pearls

  • DIC is a consumption coagulopathy involving both microvascular thrombosis and bleeding.
  • Tissue factor-driven coagulation activation is an important mechanism.
  • The classical laboratory pattern is prolonged PT/aPTT, thrombocytopenia, elevated D-dimer and reduced fibrinogen.
  • Schistocytes may appear due to microangiopathic haemolysis.
  • Sepsis is a major cause of DIC.
  • Acute promyelocytic leukaemia is a classic malignancy-associated cause.
  • Placental abruption and amniotic fluid embolism are important obstetric triggers.
  • The ISTH overt DIC score is compatible with overt DIC when the total is at least 5 in the appropriate clinical setting.
  • Treatment focuses on the underlying cause and appropriate blood component support.
  • Heparin is reserved for selected circumstances rather than routine treatment of all DIC.
Most Important Examination Point

DIC produces simultaneous systemic coagulation activation, consumption of platelets and coagulation factors, fibrin deposition and variable fibrinolysis. This explains the characteristic combination of thrombosis, bleeding and organ dysfunction.

Clinical Note

DIC is a medical emergency requiring urgent treatment of the underlying cause and careful management of bleeding, thrombosis and organ dysfunction. Transfusion and anticoagulation decisions must be individualised according to clinical circumstances and local protocols.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments